Immunotherapies for Alzheimer’s Disease

DOI

10.2991/978-2-494069-31-2_344How to use a DOI?

Keywords

Immunotherapies; Alzheimer; Anti-amyloid; Tau

Abstract

Alzheimer’s disease (AD) is the main cause of dementia and it is a neurodegeneration disease. Numerous evidence has shown that amyloid β (Aβ) and tau protein are two main “triggers” of this disease. The Aβ has been main target for decades, and this review will discuss both active anti-Aβ and passive anti-Aβ immunotherapies. Recently, the tau protein has emerged as a new leading target for AD treatment. Several active and passive anti-tau antibodies will also be discussed in this review. Finally, it provides some suggestions about the future strategies to overcome AD.

Copyright

© 2022 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Hui Guo
PY  - 2022
DA  - 2022/12/29
TI  - Immunotherapies for Alzheimer’s Disease
BT  - Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022)
PB  - Atlantis Press
SP  - 2926
EP  - 2932
SN  - 2352-5398
UR  - https://doi.org/10.2991/978-2-494069-31-2_344
DO  - 10.2991/978-2-494069-31-2_344
ID  - Guo2022
ER  -